Anaphylaxis
Risk of severe allergic reaction. Seek urgent medical help if serious symptoms occur.
Medicine information SYNAGIS 50mg powder and solvent for solution for injection
- Product code:
- W64706001
- Quantity:
- 1
- Indicated for:
- prevention of respiratory syncytial virus disease
- Route of administration:
- injectable
- Substance:
- palivizumab (monoclonal antibody)
- ATC
- J06BB16 — Antiinfectives for systemic use | Immunoglobulins | Specific immunoglobulins
Palivizumab is a monoclonal antibody used for the prevention of severe respiratory syncytial virus (RSV) infections in infants and children at high risk. It works by binding to the F protein of the virus, preventing its replication.
The medication is administered via intramuscular injection, usually once a month during the RSV season, as directed by your doctor. It is important to follow the administration schedule to ensure optimal protection.
Side effects may include injection site reactions, fever, rash, or, in rare cases, severe allergic reactions.
Patients should inform their doctor about any known allergies or other conditions to ensure the safe use of palivizumab.
The medication is administered via intramuscular injection, usually once a month during the RSV season, as directed by your doctor. It is important to follow the administration schedule to ensure optimal protection.
Side effects may include injection site reactions, fever, rash, or, in rare cases, severe allergic reactions.
Patients should inform their doctor about any known allergies or other conditions to ensure the safe use of palivizumab.
General data about SYNAGIS 50mg
- Substance:
- palivizumab
- Date of latest medicines list:
- 01-07-2020
- Product code:
- W64706001
- Strength:
- 50mg
- Pharmaceutical form:
- powder and solvent for solution for injection
- Quantity:
- 1
- Product type:
- Original
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for palivizumab
Strengths available for palivizumab
- 100mg
- 100mg/ml
- 50mg
Official documents
The SmPC text is not displayed because a match to this medicine, strength and pharmaceutical form has not been confirmed.
- Added to database:
- 04/12/2009
- Source record updated:
- 11/10/2023
Warnings:
Additional monitoring
This medicine is subject to additional monitoring.
Breastfeeding warning
Use during breastfeeding only on medical advice.
Pregnancy warning
Use during pregnancy only on medical advice.